Want to see STXS full AI Analyst Report?
STXS Stock Chart & Stats
$1.33
$0.00(0.00%)
At close: 4:00 PM EDT
$1.33
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.24 - $3.59
Previous Close$1.33
Volume443.78K
Average Volume (3M)1.04M
Market Cap
$125.36M
Enterprise Value$177.86
Total Cash (Recent Filing)$14.62M
Total Debt (Recent Filing)$5.28M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding97,934,074
10 Day Avg. Volume1,918,848
30 Day Avg. Volume1,043,755
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.17Price Target Upside213.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$39.40M
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalsRecent FDA clearances (PMA for MAGIC, Synchrony clearance and prior Genesys X clearance) provide a durable regulatory foundation that materially expands the company's addressable market. Regulatory approval reduces commercialization risk, enables broader system placements and recurring consumable sales, and supports multi-year adoption and reimbursement conversations essential for sustained revenue growth.
High Disposable EconomicsConsumable revenue per procedure being consistently high creates a scalable, recurring revenue stream that is less lumpy than capital system sales. Durable per-procedure economics support margin expansion and cash generation as utilization grows, allowing the company to monetize installed systems through repeat sales of disposables and reduce reliance on one-off system placements over the medium term.
Robocath AcquisitionThe Robocath acquisition structurally broadens Stereotaxis' product footprint into vascular robotics and neurointerventions, expanding TAM and creating cross-sell and R&D synergies. If integration succeeds, the deal accelerates next‑generation product development and creates long-term commercialization pathways across multiple endovascular specialties, strengthening strategic positioning.
Bears Say
Sustained Cash BurnLarge and persistent negative operating and free cash flows indicate the business consumes significant cash to fund operations and growth. Ongoing cash burn raises financing needs and dilution risk, constrains the company's ability to invest in manufacturing and commercial scale, and makes execution of the disposable-driven growth plan contingent on securing additional capital or rapid margin improvement.
Modest Cash RunwayA cash balance of ~$14.6M against negative quarterly free cash flow and integration costs for Robocath implies a limited runway. Management's characterization of a 'delicate balancing act' signals that near-term financing or operational tightening may be required, which can pressure strategic flexibility and increase the probability of dilution before the company reaches sustainable positive cash generation.
Manufacturing & Transition HeadwindsProduction capacity limits and the messy transition from the J&J catheter relationship have directly constrained procedures and recurring revenue. Until manufacturing and supply transitions are fully resolved, the company may underdeliver on disposable volume, delay revenue recognition, and struggle to convert early clinical interest into sustained commercial utilization, creating execution risk to guidance.
Stereotaxis News
STXS FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was $1.24 and its highest was $3.59 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is $125.36M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is Aug 11, 2026 which is in 11 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on May 12, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.01.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.05.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 97,934,074 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -3.646%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in STXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stereotaxis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.17 (213.28% Upside)
$4.17 (213.28% Upside)
Blogger Sentiment
Bullish
STXS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 126.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.7%
Last 30 Days ▲ 55.7%
Last 30 Days ▲ 55.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
18.21%
Trailing 12-Months
Company Description
Stereotaxis
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
STXS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced transformational strategic progress with near-term execution and financial headwinds. Major positives include multiple recent FDA approvals (MAGIC, Synchrony), successful early clinical use of the MAGIC catheter, a clear disposable revenue opportunity (disposables often >$5k–$8k per procedure), Genesys X and Synchrony commercialization steps, and the Robocath acquisition that strengthens long-term robotics strategy. Offsetting these are short-term declines in reported revenue (Q1 revenue down ~16%), capacity constraints and supply transition issues due to winding down the Johnson & Johnson relationship, continued operating losses, and increasing negative free cash flow. Management reiterated >$40M revenue guidance for 2026 and described a path to ramp and profitability, but achieving that depends on manufacturing ramp, adoption of disposables, and execution of capital sales.View all STXS earnings summariesSTXS Stock 12 Month Forecast
Average Price Target
$4.17
▲(213.28% Upside)
Technical Analysis
Atricure
―
Lemaitre Vascular
―
Merit Medical Systems
―
Staar Surgical
―
Milestone Scientific
―
Ownership Overview
20.76% Insiders
6.55% Mutual Funds
1.50% Other Institutional Investors
64.96% Public Companies and
Individual Investors